Menopause

Mithra Appoints Experienced Life Sciences Executive Christian Homsy* as Chairman

Inge Beernaert appointed President of the Compensation and Nomination CommitteeJacques Galloy appointed President of the Audit CommitteeLiege, Belgium, 29 May…

2 years ago

Daré Bioscience Reports First Quarter 2023 Financial Results and Provides a Company Update

Conference Call and Webcast Today at 4:30 p.m. ET 2023 Anticipated Milestones: Sildenafil Cream, 3.6% for Female Sexual Arousal Disorder…

2 years ago

Daré Bioscience to Host First Quarter 2023 Financial Results and Company Update Conference Call and Webcast on May 11, 2023

SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today…

2 years ago

Menopause Luminary, Dr. Steven R. Goldstein, Joins Entera’s Clinical and Scientific Advisory Board

JERUSALEM, April 26, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”) a leader in the…

2 years ago

Daré Bioscience Announces Initiation of Subject Enrollment in a Phase 1 Thermography Study to Support Pharmacodynamic and Pharmacokinetic Characterization of Sildenafil Cream, 3.6%

Phase 1 Thermography Study Quantitative Data Expected to Complement Patient Reported Outcome Data Collected in the Exploratory Phase 2b RESPOND…

2 years ago

Daré Bioscience to Participate in Xpectives.Health SUMMIT Innovations in Women’s Health Business Conference

SAN DIEGO, April 17, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today…

2 years ago

Daré Bioscience Reports Full Year 2022 Financial Results and Provides a Company Update

Conference Call and Webcast Today at 4:30 p.m. ET 2022 Daré Key Portfolio Accomplishments: License Agreement with Organon to Commercialize…

2 years ago

Daré Bioscience to Host Full-year 2022 Financial Results and Company Update Conference Call and Webcast on March 30, 2023

SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today…

2 years ago

Acer Therapeutics Announces Topline Results from ACER-801 (Osanetant) Phase 2a Trial

ACER-801 safe and well-tolerated but did not achieve statistically significant decrease in frequency or severity of hot flashes in postmenopausal…

2 years ago